← GEN Restaurant Group, Inc. (GENK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
GEN Restaurant Group, Inc. (GENK)
Retail-Eating Places · market cap $70M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
GEN Restaurant Group (GENK) operates 43 all-you-can-eat Korean BBQ restaurants concentrated in the Western U.S., generating $208M in 2024 revenue with a $70M market cap at ~$1.73/share. The FACTS provided reference a drug asset (SUL-238, Phase 2 for Parkinson's Disease) that has no evident connection to a restaurant company — this appears to be a data mismatch or error in the source material, and no pipeline value can be responsibly assigned. The company carries $9.5M net debt against only $4.4M cash, flagging a tight balance sheet.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SUL-238 (1500 mg t.i.d.) film-coated tablets | Phase 2 | Parkinson's Disease (PD) |
Price & technical context
3-month
+0.5%
6-month
-15.8%
12-month
-43.5%
52-wk range
$1.46–$4.71
vs 50-day MA
+4.6%
vs 200-day MA
-8.8%
Realized vol
73.0%
Max drawdown
-87.3%
Daily closes through 2026-06-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GENK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.